David Borg
16 – 24 of 24
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2017
-
Mark
The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : A multicentre, open-label, randomised, phase 3 trial
(
- Contribution to journal › Article
- 2016
-
Mark
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.
(
- Contribution to journal › Article
-
Mark
Pancreatic cancer : Yesterday, today and tomorrow
(
- Contribution to journal › Article
-
Mark
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma
(
- Contribution to journal › Article
- 2015
-
Mark
Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
2015) In Histopathology(
- Contribution to journal › Article
- 2009
-
Mark
Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »